News & Press Releases

Steven Shparber, Co-chair of Mintz’s Digital Infrastructure Practice, recently spoke with Data Center Knowledge about the growing use of behind-the-meter power by data center operators as they face grid delays and rising AI-driven demand.

Mintz advised the placement agent in connection with ImageneBio’s $30 million private placement of pre-funded warrants.

Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.

David Adams was quoted in a CFO Dive article analyzing the challenges facing efforts to pass comprehensive federal AI legislation, and what the ongoing political gridlock and competing state-level approaches mean for businesses.

Of Counsel Michelle Capezza was quoted in a Business Insider article examining the push to expand private credit and other alternative investments into 401(k) retirement plans. The article discusses these developments in light of new regulations proposed by the Department of Labor, as well as ongoing questions about liquidity, valuation, and market volatility within the private credit space.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.